Epizyme CEO to step down as company plans to extend cancer drug's reach

After six years in the CEO position, Epizyme leader Robert Bazemore is stepping aside, moving into a consultant role as biotech veteran Grant Bogle takes the reins.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.